IOL Chemicals & Pharmaceuticals Ltd Q2 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/3te2vn8trkz1tmwe9qsc6x5w.pdf

Key Takeaways


Margin Walk: Pharma Heals, Chemicals Bleeds

Mahajan: "It is single digit. I think not more than that."

Paracetamol: The Volume-Price Disconnect

Mahajan: "The prices were drastically down during June and September quarter."

Non-Ibuprofen API: The Diversification Engine

Singh: "Surely we are very hopeful about meeting our targets of around Rs 500 to 550 crore non-ibu business in this financial year."

Ibuprofen: Steady but Geographically Skewed


Chemical Segment: New Capacity, Old Headwinds

Singh: "I can say in that respect, every financial year, Q2 remains on the lower side and the Q4 remains on the higher side."

Capital Allocation & Balance Sheet

Mahajan: "Definitely. We have the projections and the estimates relating to the CAPEX's, the cash generations from the businesses is more than what we are looking to invest into the CAPEX."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth~10% every yearFY24 and FY25
EBITDA margin15% to 17%FY24 and FY25
Non-ibuprofen API revenue₹500 to ₹550 croreFY24
Non-ibuprofen API growth rate20% to 25%Next 2–3 financial years
Quarterly recovery pathQ3 similar to Q2; most recovery in Q4FY24
Ibuprofen revenuesSustain at current levelsH2 FY24
Power/fuel expensesDecrease slightlyComing quarter
Overall marginsDefinite improvementNext six months
CAPEX run-rate~₹200 crore per yearFY24 and next 2–3 years
Paracetamol expansion updateManagement to provide detailsNext quarter

Key Metrics

MetricQ2 FY24
Total income₹552 cr, vs ₹546 cr in Q2 FY23 and ₹570 cr in Q1 FY24
EBITDA₹71 cr, vs ₹37 cr in Q2 FY23 and ₹80 cr in Q1 FY24
EBITDA margin12.9%, improved 620 bps YoY from 6.7%; 14% in Q1 FY24
Net profit₹38 cr, vs ₹16 cr in Q2 FY23 and ₹46 cr in Q1 FY24
EBIT margin – pharmaceutical segment15%
EBIT margin – specialty chemical segment1.5%
Revenue growth guidance~10% every year for FY24 and FY25
EBITDA margin guidance15% to 17% for FY24 and FY25
CAPEX incurred H1 FY24₹114 cr, vs ₹211 cr for full FY23; full-year plan ~₹200 cr
Ibuprofen capacity utilization~90%
Paracetamol capacity utilization90%–95%, capacity recently increased from 1,800 to 3,600
Non-ibuprofen API growth guidance20% to 25% for next 2–3 financial years
Other API revenue guidance FY24₹500 to ₹550 cr, H1 at ~₹236 cr
Global market share – ibuprofen35%
Cash and equivalents>₹250 cr, company totally debt free, no debt raised since 2017